This week’s Immunology update highlights regulatory progress, clinical momentum, financing activity, commercial deals, and early pipeline reprioritization across autoimmune and inflammatory diseases.
In Today’s Newsletter
Dive deeper
💊 Dupixent expands in pediatric CSU [1] [EU • 13 Apr 2026]
https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-13-05-00-00-3272182
Context: European Commission approved Dupixent (dupilumab; Sanofi, Regeneron) for moderate-to-severe chronic spontaneous urticaria in children aged 2–11 years with inadequate response to H1 antihistamines and who are naïve to anti-IgE therapy.
Key point: The approval extends EU CSU use into younger children, supported by LIBERTY-CUPID data, including adult Phase 3 efficacy extrapolation plus pediatric PK, safety, and efficacy data.
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 CD19 CAR-T induces triple autoimmune remission in one patient [2] [Germany • 09 Apr 2026]
https://www.fiercebiotech.com/research/first-car-t-cell-therapy-drives-3-autoimmune-diseases-remission-once
Context: A Med case report described a 47-year-old woman with autoimmune hemolytic anemia, antiphospholipid syndrome, and immune thrombocytopenia treated at University Hospital Erlangen with zorpocabtagene-autoleucel (zorpo-cel; Miltenyi Biomedicine).
Key point: The patient was reported to be in remission across all three diseases 11 months after treatment, with no cytokine release syndrome or ICANS reported.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
🏥 Remission Medical raises Series A for virtual rheumatology growth [3] [US • 13 Apr 2026]
https://www.prnewswire.com/news-releases/remission-medical-closes-series-a-led-by-blue-heron-capital-to-expand-virtual-rheumatology-partnerships-across-us-health-systems-302740483.html
Context: Remission Medical said Blue Heron Capital led its Series A, with proceeds earmarked for health system expansion, workforce growth, and scaling its RemissionOS platform.
Key point: The company said it embeds APP-led rheumatology capacity into partner health systems and is already active with named partners including Sentara, WellSpan, Ochsner, MultiCare, and others.
Implication: May expand screening, initiation, and follow-up at scale.
💉 Saphnelo SC wins Canada approval in SLE [4] [Canada • 13 Apr 2026]
https://biomb.ca/saphnelo-subcutaneous-approved-in-canada-for-the-treatment-of-systemic-lupus-erythematosus/
Context: Health Canada granted a Notice of Compliance for Saphnelo subcutaneous autoinjector (anifrolumab) for adults with active, autoantibody-positive systemic lupus erythematosus, in addition to standard therapy.
Key point: The approval was based on an interim Phase 3 TULIP-SC analysis showing a statistically significant and clinically meaningful reduction in disease activity versus placebo.
Implication: May influence prescriber choice and payer reviews pending full data.
🧫 Spyre posts Phase 2 UC signal for SPY001 [5] [13 Apr 2026]
https://www.fiercebiotech.com/biotech/spyre-points-phase-2-win-ulcerative-colitis-drug-proof-it-could-take-takedas-entyvio
Context: In Part A of the Skyline trial, Spyre Therapeutics tested SPY001, an anti-α4β7 antibody, in 43 patients with moderately to severely active ulcerative colitis.
Key point: At Week 12, SPY001 met the key goal on Robarts Histopathology Index reduction; the company also highlighted clinical remission and endoscopic improvement, with safety described as consistent with the α4β7 class.
Implication: May influence prescriber choice and payer reviews pending full data.
🖥️ Almirall deepens AI and supercomputing dermatology alliance [6] [Spain • 13 Apr 2026]
https://www.businesswire.com/news/home/20260413473335/en/Almirall-and-Barcelona-Supercomputing-Center-Expand-Their-Collaboration-to-Accelerate-Innovation-in-Medical-Dermatology
Context: Almirall and the Barcelona Supercomputing Center expanded their collaboration under a new framework agreement focused on AI, HPC, and medical dermatology R&D.
Key point: Almirall will join the BSC Connects program to access training, technology, and co-development support for projects across 2026.
Implication: Signals pipeline investment and modality expansion.
🌏 LEO Pharma takes Spevigo rights in Korea [7] [Korea • 10 Apr 2026]
https://www.koreabiomed.com/news/articleView.html?idxno=31261
Context: LEO Pharma said it acquired Korean marketing authorization for Spevigo (spesolimab) from Boehringer Ingelheim, effective 16 Mar 2026, for acute flares in adults with generalized pustular psoriasis.
Key point: The transfer gives LEO Pharma an end-to-end psoriasis and dermatology portfolio in Korea, spanning topical therapy to treatment for rare severe flare settings.
Implication: Introduces competition that may affect pricing and formulary access.
🗑️ Boehringer and Amgen trim early immunology pipelines [8] [14 Apr 2026]
https://www.fiercebiotech.com/biotech/boehringer-amgen-discard-early-immunology-candidates-due-lack-clinical-potential
Context: Boehringer Ingelheim halted BI 3009947 after a Phase 1 study in 40 healthy men, while Amgen stopped AMG 378 after a Phase 1 study in 48 healthy volunteers.
Key point: Both companies attributed the decisions to limited clinical promise or low likelihood of success, with no safety concern cited for BI 3009947.
Implication: Signals pipeline investment and modality expansion.
Why it matters
- Dupixent’s EU pediatric CSU approval [1] broadens biologic use earlier in the care pathway for a hard-to-control inflammatory skin condition.
- The zorpo-cel case [2] adds to momentum behind B-cell reset strategies in autoimmunity, but remains a single-patient report.
- Remission Medical’s financing [3] shows continued investor interest in access-focused specialty care models, especially where physician shortages are acute.
- Saphnelo SC in Canada [4] adds a self-administration option in lupus, which could matter for convenience, site-of-care decisions, and persistence.
- Spyre’s SPY001 data [5] sharpen competitive attention on next-generation IBD antibodies, while Boehringer and Amgen’s cuts [8] underscore how quickly early immunology programs can be reprioritized.
🎬 Watch on YouTube the Top Immunology news from the past two weeks, curated by the LucidQuest team.
📚 View the full Immunology archive on our research hub page.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
FAQ
What changed for Dupixent in chronic spontaneous urticaria?
Dupixent (dupilumab) was approved in the EU for children aged 2–11 years with moderate-to-severe CSU who remain uncontrolled on H1 antihistamines and are naïve to anti-IgE therapy [1]. This extends the prior EU CSU label beyond adults and adolescents [1].
How strong is the CAR-T remission story for zorpo-cel?
The report describes one patient with three autoimmune diseases entering remission 11 months after CD19 CAR-T treatment with zorpo-cel [2]. It is notable, but it is still a case report rather than randomized trial evidence [2].
What is new about Saphnelo in Canada?
Health Canada cleared a subcutaneous autoinjector version of Saphnelo (anifrolumab) for adults with active, autoantibody-positive SLE on standard therapy [4]. The source attributes the decision to interim Phase 3 TULIP-SC results [4].
Why are investors watching Spyre’s SPY001 program?
Spyre reported that SPY001 hit the key goal in Phase 2 ulcerative colitis and framed the profile as potentially competitive with vedolizumab-based therapy [5]. The same Skyline platform also includes SPY002 and SPY003 readouts later in 2026 [5].
What does Remission Medical actually sell to health systems?
Remission Medical says it embeds APP-led rheumatology care inside existing health system workflows and payer structures, supported by its RemissionOS platform [3]. The model is positioned as a way to add specialty capacity faster than building a service line from scratch [3].
What do the Boehringer and Amgen program cuts signal?
The BI 3009947 and AMG 378 discontinuations show continued portfolio tightening in early immunology, especially when Phase 1 findings do not support a clear path forward [8]. Both companies remain active in broader inflammation and immunology work [8].
Entities / Keywords
Dupixent (dupilumab), Sanofi, Regeneron, chronic spontaneous urticaria, CSU, LIBERTY-CUPID, CUPIDKids
Miltenyi Biomedicine, zorpocabtagene-autoleucel, zorpo-cel, CD19 CAR-T, autoimmune hemolytic anemia, AIHA, antiphospholipid syndrome, APLAS, immune thrombocytopenia, ITP
Remission Medical, Blue Heron Capital, virtual rheumatology, RemissionOS, APPs, health system partnerships
Saphnelo, anifrolumab, systemic lupus erythematosus, SLE, TULIP-SC, Health Canada
Spyre Therapeutics, SPY001, anti-α4β7, ulcerative colitis, UC, Skyline trial, Entyvio, vedolizumab
Almirall, Barcelona Supercomputing Center, BSC, BSC Connects, medical dermatology, high-performance computing, HPC, artificial intelligence, AI
LEO Pharma, Spevigo, spesolimab, generalized pustular psoriasis, GPP, Korea
Boehringer Ingelheim, BI 3009947, Amgen, AMG 378, immunology pipeline, Phase 1
References